Quick Answer
InMed Pharmaceuticals Inc. reported Gross Profit of $1.71 million for fiscal year 2025.
InMed Pharmaceuticals Inc. Gross Profit — Annual History
| Fiscal Year | Gross Profit | YoY Change |
|---|---|---|
| 2025 | $1.71M | +55.0% |
| 2024 | $1.10M | -21.5% |
| 2023 | $1.40M | +158.1% |
| 2022 | $543.5K | — |
Quarterly Gross Profit
| Quarter Ending | Gross Profit | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $184.2K | -60.0% | -54.3% |
| September 30, 2025 | $403.2K | -18.3% | +129.6% |
| March 31, 2025 | $175.6K | -39.3% | -61.9% |
| December 31, 2024 | $460.9K | +42.2% | -6.6% |
| September 30, 2024 | $493.4K | +2222.8% | +70.5% |
| March 31, 2024 | $289.5K | +50.4% | -10.7% |
| December 31, 2023 | $324.1K | +147.1% | +1425.9% |
| September 30, 2023 | $21.2K | +104.3% | -89.0% |
- InMed Pharmaceuticals Inc. showed an increase of +55.0% in Gross Profit compared to the prior fiscal year.
- Over the 2022–2025 period, InMed Pharmaceuticals Inc.’s gross profit has grown by 214.0% (from $543.5 thousand to $1.71 million).
- The most recent figure is from InMed Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: